Immun-oncology Models
Antibody Drug Conjugate Assay
Systemic cytotoxicity of oncological therapies is still a major problem in the clinical space, often preventing the approval of novel therapies. Antibody drug conjugates (ADC) are a targeted cancer therapy, linking a monoclonal antibody specific to cancer cell antigen and a cytotoxic drug. This facilitates the direct interaction of the conjugate with the tumour, increasing therapy effectiveness, whilst reducing off-target effects. Our in vitro antibody drug conjugate assay tests the efficacy of the novel conjugates, assessing ADC-antigen selectivity, alongside the degree of ADC driven cell death.
Available formats
Standard 96-well format.
Alternative format offerings available upon request.
Pilot assay development is available as a standalone service, or as a built in checkpoint for full studies.
FAQ
ADC assays evaluate the targeting, internalisation, and cytotoxic activity of antibody–drug conjugates. They assess how effectively the antibody delivers its payload to antigen-expressing cells.
Cellomatics uses high-content imaging and flow cytometry to track binding, internalisation, and intracellular trafficking of ADCs, ensuring that payload delivery is target-specific.
Both 2D monocultures and 3D tumour spheroid models are employed to replicate tumour architecture and microenvironment, improving translational relevance; at Cellomatics, these models are further enhanced using primary human cells and co-culture systems to better reflect in vivo tumour–immune interactions.
Dose–response studies are conducted to determine potency (e.g., IC50) and antigen-specific cytotoxicity, providing a detailed assessment of ADC performance. At Cellomatics, this is carried out using optimised cell-based assays across 2D and 3D tumour models, combined with high-content imaging and viability readouts to generate accurate, reproducible potency and selectivity data.
Cellomatics combines expertise in immuno-oncology with bespoke assay design and advanced analytical platforms. This ensures generation of high-quality, reproducible data to support ADC optimisation and accelerate preclinical development.